Cagrilintide 10mg

Cagrilintide is a long‑acting analogue of pancreatic amylin. By mimicking the physiological actions of native amylin, it targets both the amylin receptor and the calcitonin receptor—hence its classification as a dual amylin and calcitonin receptor agonist (DACRA)—to regulate appetite and energy metabolism.

Unlike commonly used GLP‑1 receptor agonists (e.g., semaglutide), Cagrilintide acts through an independent pathway. Therefore, it may be used as a monotherapy or in combination with GLP‑1‑based agents to enhance weight‑loss efficacy.

The purity of our Cagrilintide products is ≥99%. Each batch is independently tested by a third‑party laboratory using HPLC and mass spectrometry (MS), and a complete Certificate of Analysis (COA) is provided for each batch.

No. The Cagrilintide sold on our website is a research-grade product, intended solely for use in in vitro laboratory research and not for human injection, clinical treatment, or any commercial applications. Cagrilintide is still in the clinical research stage and has not yet been approved for commercial use as a drug.

The freeze‑dried powder can be stored at room temperature (in its original packaging) for several days to several weeks. For long‑term storage, it is recommended to freeze at ‑20°C and protect from light. After reconstitution, it should be stored refrigerated (at 4°C) and should not be frozen.

Yes. Cagrilintide monotherapy produces a meaningful weight-loss effect (−12% at 68 weeks in REDEFINE-1) and is appropriate for amylin-· Obesity and weight management

· Type 2 diabetes and glycemic control

· Appetite and energy intake regulation

· Non‑alcoholic fatty liver disease (NAFLD)

· Cardiovascular risk factors (e.g., blood lipids, blood pressure)receptor mechanistic research. However, for most modern obesity research, the combination protocol is more representative of likely clinical deployment.